Výsledky vyhledávání

Akademický článek

Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies

Autor: Philip J. Mease, Joseph F. Merola, Yoshiya Tanaka, Laure Gossec, Iain B. McInnes, Christopher T. Ritchlin, Robert B. M. Landewé, Akihiko Asahina, Barbara Ink, Andrea Heinrichs, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Laura C. Coates

Publikováno v: Rheumatology and Therapy, Vol 11, Iss 5, Pp 1363-1382 (2024)

Abstract Introduction Psoriatic arthritis (PsA) is a chronic inflammatory disease requiring long-term treatment. Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, has demonstrated tolerabili

Externí odkaz: https://doaj.org/article/4bbb5fc59b154e17b4cb6d05b6603d8e

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Assessing safety and efficacy of TNFi treatment in late onset ankylosing spondylitis: a TURKBIO registry study

Publikováno v: Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)

Abstract Clinical data on the use of tumour necrosis factor inhibitors (TNFi) in late-onset ankylosing spondylitis (LoAS) are limited. The present study aimed to evaluate efficacy, safety, and treatment adherence associated with the initial use of TN

Externí odkaz: https://doaj.org/article/07ea3304416b46ad8c900013a1ca1f33

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled study

Autor: Alexis Ogdie, Joseph F. Merola, Philip J. Mease, Christopher T. Ritchlin, Jose U. Scher, Kimberly Parnell Lafferty, Daphne Chan, Soumya D. Chakravarty, Wayne Langholff, Yanli Wang, Olivia Choi, Yevgeniy Krol, Alice B. Gottlieb

Publikováno v: BMC Rheumatology, Vol 8, Iss 1, Pp 1-12 (2024)

Abstract Background Tumor necrosis factor inhibitors (TNFi) are frequently chosen as the first biologic for patients with psoriatic arthritis (PsA). Given that many patients with PsA are TNFi inadequate responders (TNF-IR; either inadequate efficacy

Externí odkaz: https://doaj.org/article/8af8899c7fd64bf9a16ff7465d160dd3

Zobrazit plný text záznamu

Akademický článek

Sustained low functional impairment in axial spondyloarthritis (axSpA): which are the primary outcomes that should be targeted to achieve this?

Autor: Walter P. Maksymowych, Robert D. Inman, Louis Bessette, Proton Rahman, Emmanouil Rampakakis, Odalis Asin-Milan, Meagan Rachich, Anne Marilise Marrache, Allen J. Lehman

Publikováno v: Arthritis Research & Therapy, Vol 25, Iss 1, Pp 1-9 (2023)

Abstract Objectives To (i) determine whether sustained disease activity states, as measured by Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS), impact function, and (ii) evaluate c

Externí odkaz: https://doaj.org/article/9279f4b69de74911a73889114a9b86b8

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis

Autor: Michael V. Chiorean, Jessica R. Allegretti, Puza P. Sharma, Benjamin Chastek, Leonardo Salese, Elizabeth J. Bell, Jesse Peterson-Brandt, Joseph C. Cappelleri, Xiang Guo, Nabeel Khan

Publikováno v: BMC Gastroenterology, Vol 22, Iss 1, Pp 1-11 (2022)

Abstract Background Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of UC. We aimed to describe the real-world treatment experience and corticosteroid utilisation of patients treated with tofacitinib in a US claims database. Me

Externí odkaz: https://doaj.org/article/c135ecefb26f443b91dd22c714975ed3

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Case report: Unusual development of hepatocellular carcinoma during immunosuppressive treatments against rheumatoid arthritis overlapping Sjögren’s syndrome; cirrhotic steatohepatitis with liver inflammation and fibrosis lurks in autoimmune disorders

Autor: Shuhei Yoshida, Masashi Fujita, Teruhide Ishigame, Yasuyuki Kobayashi, Yuya Sumichika, Kenji Saito, Haruki Matsumoto, Jumpei Temmoku, Yuya Fujita, Naoki Matsuoka, Tomoyuki Asano, Shuzo Sato, Hiroshi Watanabe, Hiroshi Yoshida, Shigeru Marubashi, Yuko Hashimoto, Hiromasa Ohira, Kiyoshi Migita

Publikováno v: Frontiers in Immunology, Vol 14 (2023)

The sequential progression from chronic liver disease to cirrhosis may be a risk factor for hepatocellular carcinoma (HCC) development. Although HCC originates from hepatitis B virus- or hepatitis C virus-associated liver cirrhosis, it has recently b

Externí odkaz: https://doaj.org/article/2c44a71656334a14903be9f79ecc5140

Zobrazit plný text záznamu

Akademický článek

Machine learning-based prediction model for responses of bDMARDs in patients with rheumatoid arthritis and ankylosing spondylitis

Autor: Seulkee Lee, Seonyoung Kang, Yeonghee Eun, Hong-Hee Won, Hyungjin Kim, Jaejoon Lee, Eun-Mi Koh, Hoon-Suk Cha

Publikováno v: Arthritis Research & Therapy, Vol 23, Iss 1, Pp 1-12 (2021)

Abstract Background Few studies on rheumatoid arthritis (RA) have generated machine learning models to predict biologic disease-modifying antirheumatic drugs (bDMARDs) responses; however, these studies included insufficient analysis on important feat

Externí odkaz: https://doaj.org/article/2f16bd9de5574376b131133d508f920b

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání